CHC 2017

Canadian Hematology Conference

The 7th Annual Canadian Hematology Conference (CHC 2017) was a great success!

The 7th annual Canadian Hematology Conference took place on September 29th and 30th, 2017 at the Shangri-La hotel in Toronto, Ontario. CARE was please to welcome a diverse and well reputed Faculty of over 30 Canadian and international opinion leaders who provided highly informative, cutting-edge presentations on a variety of hematological topics.

CHC is the largest multidisciplinary hematology focused meeting in Canada and CHC 2017 was the largest to date. Two full days of presentations and symposia directed at academics, clinicians, trainees and allied health care providers (nurses and pharmacists). Content included malignant and benign hematology as well as translational science.

This year’s conference agenda was designed to cover the most exciting and important categories in hematology, while also providing insights and information relevant to Canadian practice. The CHC 2017 Conference Report provides a summary of the robust content presented during CHC plenary sessions and symposia.

Location:

Shangri-La Hotel
188 University Ave, Toronto, ON M5H 0A3

Date:

September 29-30, 2017

Conference Chairs:

Dr. John Kuruvilla, MD, FRCP(C) – (Hematologist, Princess Margaret Cancer Centre)
Dr. Peter Anglin, MD, FRCP(C) – (Internal Medicine Hematology, Stronach Regional Cancer Centre)

Speaker Presentations:

Day One

Chronic Lymphocytic Leukemia (CLL)
Chair – Dr. Graeme Fraser
Update on Standard Therapy of CLL
Management of Ibrutinib Failure

View Slides

Hodgkin’s Lymphoma
Chair – Dr. Michael Crump
Current Management of Localized HL
Risk Adapted Therapy in Advanced HL: Current Approaches

View Slides

Non-Hodgkin’s Lymphoma
Chair – Dr. Laurie Sehn
Evolving Standards in Follicular Lymphoma
Novel Therapy in Follicular Lymphoma
The Genomics of Follicular Lymphoma

View Slides

Leukemia/Myelodysplastic Syndrome (MDS)
Chair – Dr. Rena Buckstein
Treatment in 2017 – “Nuts and Bolts” of AML Therapy
The Impact of Somatic Mutations for Patients with MDS
Managing Patients with Azacitidine Failure in MDS

View Slides

Benign Hematology I
Chair – Dr. Denis Soulieres
Catheter Related Thrombosis
Current Management of Clinical Hemoglobinopathy

View Slides

Immunotherapy
Chair – Peter Anglin
The Future of Immunotherapy in Lymphoma: Dr. Stephen Ansell

View Slides

Day Two

Benign Hematology II
Chair – Dr. Martina Trinkaus
Off Label Evidence for DOACs in Cancer and DOAC Reversal
Review of Erythropoiesis-Stimulating Agents in 2017
The Refractory AIHA Patient

View Slides

Non-Hodgkin’s Lymphoma II
Chair – Dr. Douglas Stewart
PET in Lymphoma: How to Use New Staging & Response Criteria
Management of Double Hit and Dual Protein Expressing Lymphomas
ASCT in Primary and Secondary CNS Lymphoma

View Slides

Myeloma
Chair – Dr. Kevin Song
Monoclonal Gammopathies of Renal Significance
Relapsed/Refractory Disease

View Slides

Translational I
Chair – Dr. Rob Laister
The Development of CRISPR Based Medicines for the Treatment of Hematological Diseases
Anti-Tumour Immunity: Beyond T-Cells and Checkpoint Blockades
Emerging Concepts in Cell Therapy and The Microenvironment

View Slides

Translational II
Chair – Dr. John Kuruvilla
The Tumour Microenvironment of B-Cell Lymphomas
Cellular Therapy and the Future of Allogeneic Steam Cell Transplantation

View Slides

Myeloproliferative Neoplasms (MPN)
Chair – Dr. Lynda Foltz
Update on JAK Inhibitors in 2016-2017
Case Studies in MPN

View Slides